M&A Deal Summary

Astellas Pharma Acquires Audentes Therapeutics

On December 2, 2019, Astellas Pharma acquired life science company Audentes Therapeutics for 3.0B USD

Acquisition Highlights
  • This is Astellas Pharma’s 10th transaction in the Life Science sector.
  • This is Astellas Pharma’s 3rd largest (disclosed) transaction.
  • This is Astellas Pharma’s 7th transaction in the United States.
  • This is Astellas Pharma’s 3rd transaction in California.

M&A Deal Summary
Date 2019-12-02
Target Audentes Therapeutics
Sector Life Science
Buyer(s) Astellas Pharma
Deal Type Add-on Acquisition
Deal Value 3.0B USD
Advisor(s) Centerview Partners (Financial)
Fenwick & West (Legal)

Target

Audentes Therapeutics

San Francisco, California, United States
Audentes Therapeutics, Inc. is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of AAV gene therapy technology. Audentes Therapeutics was founded in 2012 and is based in San Francisco, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Astellas Pharma

Tokyo, Japan
Category Company
Founded 1923
Sector Life Science
Employees14,754
Revenue 1.60T JPY (2024)
DESCRIPTION
Astellas office complex in Northbrook, Illinois.
Astellas office complex in Northbrook, Illinois.

Astellas Pharma is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience and DM complications and metabolic diseases. Astellas Pharma was incorporated in 1923 and is based in Tokyo, Japan.

DEAL STATS #
Overall 10 of 14
Sector (Life Science) 10 of 13
Type (Add-on Acquisition) 10 of 14
State (California) 3 of 5
Country (United States) 7 of 11
Year (2019) 1 of 2
Size (of disclosed) 3 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-14 Potenza Therapeutics

Cambridge, Massachusetts, United States

Potenza Therapeutics, Inc. is a portfolio of oncology programs that utilize the body's own immune system to seek out, recognize and destroy tumors. Potenza Therapeutics was founded in 2014 and is based in Cambridge, Massachusetts.

Buy $165M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-12-26 Xyphos Biosciences

South San Francisco, California, United States

Xyphos Biosciences, Inc. is a privately held development-stage biotechnology company, is focused on the creation and development of immuno-oncology therapeutics designed to harness the power of the patient's immune system to cure cancer. Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform allow new and potentially better ways to mobilize and control immune cells to find and destroy specifically targeted cells throughout the body.

Buy $665M
Mergr

Product

Company

Legal